DNA
36 drugs Oncology
13
approved indications
36
Approved Drugs
29
Companies
63
Indications
1
Therapeutic Areas
Top Drugs
Unlock Full Target Intelligence PRO
✓ Competitive landscape by company (29 companies)
✓ All 36 approved drugs
✓ Therapeutic area breakdown
✓ Full indication list (63 indications)
✓ Patent cliff analysis
✓ Clinical trials pipeline
Upgrade to Pro
Starting at $99/mo
Drugs by Company
Baxter 3 drugs
AVYXA HOLDINGS 2 drugs
Hikma 2 drugs
By Therapeutic Area
Oncology 22 drugs
Other 14 drugs
Drugs by Company PRO
Baxter 3 drugs
Hikma 2 drugs
MEITHEAL 2 drugs
Pfizer 2 drugs
AYANA PHARMA LTD 1 drug
PENN LIFE 1 drug
AVET LIFESCIENCES 1 drug
Bristol-Myers Squibb 1 drug
+ 19 more companies
By Therapeutic Area
Oncology 22 drugs
FRINDOVYX, CYCLOPHOSPHAMIDE, CYTOXAN, DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) +18 more
Other 14 drugs
DACTINOMYCIN, PENTAM, NELARABINE, TEPYLUTE +10 more
Indications Treated
Pneumocystis jiroveci PneumoniaKaposi's SarcomaHodgkin's DiseaseLymphocytic LymphomaMixed-Cell Type LymphomaHistiocytic LymphomaBurkitt's LymphomaMultiple MyelomaLeukemiaMycosis FungoidesNeuroblastomaAdenocarcinoma of OvaryMyelodysplastic SyndromeRefractory AnemiaRefractory Anemia with Ringed SideroblastsRefractory Anemia with Excess BlastsRefractory Anemia with Excess Blasts in TransformationChronic Myelomonocytic LeukemiaWilms TumorRhabdomyosarcomaEwing SarcomaTesticular CancerGestational Trophoblastic NeoplasiaSolid MalignanciesT-Cell Acute Lymphoblastic LeukemiaT-Cell Lymphoblastic LymphomaOvarian CarcinomaBreast CancerBrain TumorGlioblastoma + 33 more
All Drugs Targeting DNA
| Drug | Company | Approved | Indications | Therapeutic Area |
|---|---|---|---|---|
| FRINDOVYX Top | AVYXA HOLDINGS | 2023 | 13 | Oncology |
| CYCLOPHOSPHAMIDE Top | Hikma | 1986 | 10 | Oncology |
| CYTOXAN Top | Baxter | 1959 | 10 | Oncology |
| DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL) | AYANA PHARMA LTD | 2013 | 10 | Oncology |
| DOXIL (LIPOSOMAL) | Baxter | 1995 | 10 | Oncology |
| CARMUSTINE | PENN LIFE | 2018 | 9 | Oncology |
| BICNU | AVET LIFESCIENCES | 1977 | 9 | Oncology |
| VIDAZA | Bristol-Myers Squibb | 2004 | 7 | Oncology |
| AZACITIDINE | MEITHEAL | 2013 | 6 | Oncology |
| DACTINOMYCIN | MEITHEAL | 2010 | 6 | |
| ZYNLONTA | ADC Therapeutics SA | 2021 | 3 | Oncology |
| PENTAM | Fresenius Kabi | 1984 | 2 | |
| NELARABINE | XGEN PHARMS | 2021 | 2 | |
| TEPYLUTE | SHORLA | 2024 | 2 | |
| ARRANON | Novartis | 2005 | 2 | |
| XOFIGO | Bayer | 2013 | 2 | Oncology |
| PENTAMIDINE ISETHIONATE | SETON PHARMS | 1992 | 2 | |
| LOMUSTINE | CARNEGIE | 2025 | 2 | Oncology |
| GLEOSTINE | AZURITY | 1976 | 2 | Oncology |
| ZEPZELCA | JAZZ | 2020 | 2 | Oncology |
| GLIADEL | AZURITY | 1996 | 2 | Oncology |
| YONDELIS | Johnson & Johnson | 2015 | 2 | |
| KYXATA | AVYXA HOLDINGS | 2025 | 1 | Oncology |
| ELLENCE | Pfizer | 1999 | 1 | Oncology |
| ZUSDURI | UROGEN PHARMA | 2025 | 1 | |
| IFOSFAMIDE | Hikma | 2002 | 1 | |
| HEPZATO | DELCATH SYSTEMS INC | 2023 | 1 | Oncology |
| VYXEOS | JAZZ PHARMS THERAP | 2017 | 1 | Oncology |
| OXSORALEN-ULTRA | BAUSCH | 1986 | 1 | |
| IFEX | Baxter | 1987 | 1 | |
| IDAMYCIN PFS | Pfizer | 1997 | 1 | Oncology |
| IVRA | Apotex | 2023 | 1 | Oncology |
| EVOMELA | ACROTECH BIOPHARMA | 2016 | 1 | Oncology |
| BUSULFEX | OTSUKA PHARM | 1999 | 1 | |
| UVADEX | THERAKOS DEVELOPMENT | 1999 | 1 | |
| EPIRUBICIN HYDROCHLORIDE | EPIC PHARMA LLC | 2006 | - |